Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 287

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 287
---
 The BLAC M&A Committee considered the foregoing information, among the other information described herein, in its conclusion that the Business Combination is fair to, advisable, and in the best interests of BLAC and its stockholders. OSR Holdings’ Business Model The BLAC M&A Committee considered it noteworthy and meaningful from its due diligence standpoint that OSR Holdings operates a “Hub -and -Spoke” business model with a centralized portfolio management team of the holding company which owns and controls a growing portfolio of emerging biotech and medtech companies (in South Korea and Switzerland), as opposed to the traditional “single platform/single entity” biotech corporate model. OSR Holdings’ business objective is to optimize value creation for each of its product candidates and thereby continuously assess the best pathway for each, as it progresses through preclinical and clinical development processes, including through internal advancement, partnerships with established companies, and spin -outsor IPOs. OSR Holdings´ team is comprised of accomplished biopharma scientists, entrepreneurs, executives and employees with financial market, legal and medical industry experiences who bring together the interdisciplinary expertise and resources required to grow a pipeline of innovative biotech companies. As a result of discussions with the OSR Holdings management team and the RMC, Darnatein, and Vaximm management teams, the BLAC M&A Committee concluded that, as a life sciences holding company, OSR Holdings provides valuable centralized leadership and resources to its subsidiaries across therapeutic areas, target indications and technologies. While OSR Holdings and its subsidiaries are still at an early stage, the BLAC M&A Committee viewed the business model and subsidiary entities as possessing significant value and potential for future economic gains. Furthermore, OSR Holdings’ track record of executing on its business model to acquire its current subsidiaries by negotiating with their historical shareholders provided a basis for the BLAC M&A Committee to view the OSR Holdings team as capable of further scaling and supporting its subsidiary portfolios, particularly if OSR Holdings is able to secure broader access to the equity capital markets by listing on a stock exchange. In this regard, the BLAC M&A Committee also recognized that OSR Holdings played a key role in Vaximm’s engagement with one of the largest investment banks in Korea (Shinhan Investment Corp.) regarding Vaximm’s potential Korean IPO in 2020. Although the engagement did not result in further action towards Vaximm’s contemplated IPO, the engagement provided the BLAC M&A Committee with support for OSR Holdings’ capability, if and when appropriate, to provide necessary support